Q4 EPS Estimate for Eton Pharmaceuticals Boosted by Analyst

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Equities research analysts at B. Riley boosted their Q4 2025 earnings per share (EPS) estimates for Eton Pharmaceuticals in a report released on Sunday, April 27th. B. Riley analyst M. El-Saadi now expects that the company will post earnings per share of $0.33 for the quarter, up from their previous forecast of $0.25. B. Riley has a "Buy" rating and a $24.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals' current full-year earnings is ($0.14) per share.

A number of other equities research analysts also recently commented on the company. HC Wainwright reiterated a "buy" rating and issued a $33.00 price objective on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th. Craig Hallum upped their price target on Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a "buy" rating in a research note on Wednesday, March 19th.

Eton Pharmaceuticals Price Performance

Shares of Eton Pharmaceuticals stock traded up $0.37 on Tuesday, hitting $17.34. 239,854 shares of the company's stock traded hands, compared to its average volume of 181,167. The firm's 50-day moving average price is $14.28 and its two-hundred day moving average price is $13.29. The stock has a market capitalization of $465.02 million, a PE ratio of -78.82 and a beta of 1.22. Eton Pharmaceuticals has a one year low of $3.18 and a one year high of $18.41.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The company had revenue of $11.65 million during the quarter, compared to analysts' expectations of $10.53 million.

Institutional Trading of Eton Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in ETON. Nantahala Capital Management LLC increased its holdings in shares of Eton Pharmaceuticals by 12.0% in the fourth quarter. Nantahala Capital Management LLC now owns 1,118,483 shares of the company's stock worth $14,898,000 after acquiring an additional 119,750 shares in the last quarter. Westside Investment Management Inc. raised its holdings in Eton Pharmaceuticals by 5.7% during the 3rd quarter. Westside Investment Management Inc. now owns 618,675 shares of the company's stock worth $3,711,000 after buying an additional 33,275 shares during the period. Mink Brook Asset Management LLC acquired a new position in shares of Eton Pharmaceuticals in the fourth quarter valued at approximately $6,071,000. Cannell Capital LLC acquired a new stake in shares of Eton Pharmaceuticals during the fourth quarter worth $5,079,000. Finally, Parkman Healthcare Partners LLC lifted its position in Eton Pharmaceuticals by 6.4% in the 4th quarter. Parkman Healthcare Partners LLC now owns 276,890 shares of the company's stock valued at $3,688,000 after acquiring an additional 16,664 shares in the last quarter. Institutional investors and hedge funds own 27.86% of the company's stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.